{"id":56813,"date":"2026-02-10T23:50:34","date_gmt":"2026-02-10T15:50:34","guid":{"rendered":"https:\/\/flcube.com\/?p=56813"},"modified":"2026-02-10T23:50:36","modified_gmt":"2026-02-10T15:50:36","slug":"xianju-pharmaceutical-and-adamerck-grant-aspen-china-rights-to-aomeikesong-neuromuscular-reversal-agent","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56813","title":{"rendered":"Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent"},"content":{"rendered":"\n

Zhejiang Xianju Pharmaceutical Co., Ltd.<\/strong> (SHE: 002332<\/a><\/strong>) and Hangzhou Adamerck Pharmlabs Inc.<\/strong> have entered a tripartite partnership agreement<\/strong> with Aspen Holdings<\/strong> (South Africa), granting the emerging markets pharma leader exclusive promotion rights<\/strong> to aomeikesong<\/strong> in mainland China<\/strong>. The neuromuscular blockade reversal agent<\/strong>, structurally and mechanistically comparable to Merck’s Bridion (sugammadex)<\/strong>, will be co-developed and co-commercialized<\/strong> with equal revenue and profit sharing<\/strong> between the Chinese partners.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Chinese Partners<\/strong><\/td>Zhejiang Xianju Pharmaceutical (SHE: 002332) \u00d7 Hangzhou Adamerck Pharmlabs<\/td><\/tr>
Licensee<\/strong><\/td>Aspen Holdings (South Africa-headquartered)<\/td><\/tr>
Asset<\/strong><\/td>Aomeikesong \u2013 Neuromuscular blockade reversal agent<\/td><\/tr>
Mechanism<\/strong><\/td>Rocuronium\/vecuronium antagonist (sugammadex-like cyclodextrin encapsulation)<\/td><\/tr>
Territory<\/strong><\/td>Mainland China (exclusive promotion rights to Aspen)<\/td><\/tr>
Economics<\/strong><\/td>Milestone revenue and net profits equally shared<\/strong> between Xianju and Adamerck<\/td><\/tr>
Reference Product<\/strong><\/td>Merck & Co.’s Bridion (sugammadex)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Clinical Differentiation<\/h2>\n\n\n\n
Feature<\/th>Aomeikesong Specification<\/th>Competitive Advantage<\/th><\/tr><\/thead>
Target<\/strong><\/td>Rocuronium and vecuronium<\/strong> (aminosteroid NMBAs)<\/td>Rapid, complete reversal of deep neuromuscular blockade<\/td><\/tr>
Mechanism<\/strong><\/td>Cyclodextrin encapsulation<\/strong> (sugammadex-class)<\/td>Chemical antagonism vs. acetylcholinesterase inhibition<\/td><\/tr>
Safety Profile<\/strong><\/td>No muscarinic-like adverse reactions<\/strong><\/td>Avoids bradycardia, bronchospasm, and salivation seen with neostigmine\/glycopyrrolate combinations<\/td><\/tr>
Differentiation<\/strong><\/td>Same MOA as Bridion; domestic manufacturing<\/strong> potential<\/td>Cost advantage vs. imported sugammadex; supply security<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Partnership Logic<\/h2>\n\n\n\n
Partner<\/th>Strategic Value<\/th>Contribution<\/th><\/tr><\/thead>
Adamerck<\/strong><\/td>Asset originator; formulation and CMC expertise<\/td>R&D, manufacturing technology, regulatory dossier<\/td><\/tr>
Xianju Pharmaceutical<\/strong><\/td>Listed pharma with established hospital relationships<\/td>Commercial infrastructure, regulatory navigation, capital markets access<\/td><\/tr>
Aspen Holdings<\/strong><\/td>Emerging markets anesthesia leader with China presence<\/td>Dedicated anesthesia sales force, hospital formulary relationships, pricing expertise<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n